Highlight the burden and interconnected nature of cardio renal and metabolic conditions.
To increase awareness on the need for screening and diagnosis of cardio renal and metabolic conditions.
Discuss practical aspects on achieving metabolic control.
Discuss practical aspects on the early and foundational use of guideline directed organ protective therapy such as SGL T2i across cardio renal and metabolic conditions (T2D, HF and CKD) including patient ase management.

Webinar ID: 998 3535 1670

Date: 23rd March 2024, Saturday Time: 18:30:00-19:00:00 Venue: Singapore

General Practioner, London, UK

Cardiologist, Saarland University Hospital, Homburg, Germany

Endocrinologist, Director of the Royal Prince Alfred Hospital Diabetes Centre, Sydney, Australia

Endocrinology and Kidney medicine, Professor, Department of Diabetes, Monash University, Melbourne, Australia

Time	Topic	Speaker
18:00 - 18:05	The Sweet Spot: Optimising Therapies in T2DM Scope: T2D – CV and CKD risk Organ protection – ADA/EASD 2022 guidelines recommend SGLT2i in T2D with high risk/eASCVD, HF and CKD Need for early intensification of therapy for additional glycemic control- linagliptin (DPP4i add on- renal safety) +- FDC (Glyxambi)	Prof Ted Wu
18:00 - 18:05	Welcome and introduction	Dr. Maria Luisa Tiambeng
18:05 - 18:25	Multiplex screening to detect uncommon and compound EGFR mutations	Assoc Prof. Tony Lim
18:25 - 18:45	Role of TKI in EGFR uncommon and compound mutations	Dr. Satoru Miura
18:45 - 19:20	Case review & panel discussion	All

How to improve the Treatment of Advanced NSCLC Patients with Uncommon EGFR Mutations